Intrexon to collaborate with Ziopharm for graft-versus-host disease Intrexon (XON) announced it has formed a new exclusive channel collaboration with Ziopharm Oncology (ZIOP) for the treatment and prevention of graft-versus-host disease. The collaboration will focus on addressing the underlying pathologies of GvHD through engineered cell platforms to express and deliver interleukin-2. The companies plan to pursue engineered cell therapy strategies, used either separately or in combination, for targeted treatment of GvHD. The first approach is infusion of regulatory T cells conditionally expressing IL-2 utilizing Intrexon's proprietary gene control approaches such as its RheoSwitch platform. The second is deployment of orally-delivered microbe-based ActoBiotics therapeutics expressing IL-2 to modulate immune function. Under the terms of the agreement, Intrexon will receive a technology access fee of $10M in cash and reimbursement for all research and development costs. The agreement also provides for equal sharing of operating profits.